Quote: And I do agree that we should treat them formally
Quote: And I do agree that we should treat them formally with professional courtesy.
Is professional courtesy an open season on the FDA from 43,000 Cytodyn investors?
If only if the FDA would post or publish a retraction of their comment of “ No Benefit “ that would at least set the story straight and remove harm that was laid on CytoDyn internationally since we chose to take a new international path for our immediate use and possible approvals.
The FDA has to realize that they have harmed our chances everywhere in the world. This is why I believe the stock holders should have left the FDA alone in the first place and should only try to get a middle person representing us stock holders like a elected official or someone similar.
The continued assault by who knows how many of the 43,000 investors directed at the FDA might of been the reason for the letter in the first place. We can’t discount that right now. We have essentially or quite possibly been the reason we are in this position. How many investors wrote very derogatory letters and cussed them out? Shooting ourself in the foot is not the position I like to be in. Not only do we NOT have an FDA EUA but it has probably delayed our chances internationally at one and will make us prove our molecule in trials before an international or equivalent EUA in any country. Time is our injury. Cost of trials might cost us more dilution. I hate the thought of more dilution personally.
Did we screw ourselves or just delay our chances? I would think it will be on trial size that shows how much time we might of cost ourselves. Sometimes poking the bear is better served by another equally important bear like a Senator with the likes of Bernie Sanders. Someone with pull and standing that demands answers. Not an assault by thousands of investors. An all out assault by our stock holders didn’t help us is what I believe. If it continues and is ongoing... what else will we screw ourselves out of? Another possible EUA for LH’s or a BTD for Cancer? How much do we need to lose before we learn the most expensive lessons when we can’t get any approvals in the USA? Where does it stop? How much pressure is really needed by a peanut gallery of stock holders?
All I can really say... If you must be active... don’t focus on the FDA but elected officials to fight for us. Be smart in your activism. Don’t be direct by the thousands at the FDA. Know that there is 43,000 investors and the FDA will hate us for our all out assault as activists. Just please be smart!
4
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...
Continue Reading
AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...
Continue Reading
Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...
Continue Reading
AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...
Continue Reading
Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...
Continue Reading
Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...
Continue Reading
Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...
Continue Reading
Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...
Continue Reading
When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...
Continue Reading
Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...
Continue Reading
Top 5 Most Recently Viewed Articles
TechnipFMC to Present at Significant Energy Conference TechnipFMC (NYSE: FTI), a global leader in technology for both traditional and renewable energy sectors, is set to participate in a noteworthy conference. Doug Pferdehirt, who serves as the Chair and Chief Executive Officer, will take the stage at the Goldman Sachs Energy, CleanTech & Utilities Conference. The session...
Continue Reading
TPG RE Finance Trust Announces Important Q3 Earnings Release TPG RE Finance Trust, Inc. (NYSE: TRTX) is gearing up to release its financial outcomes for the third quarter of 2024. This release will occur after the market closes on an upcoming Tuesday in late October. The company also plans to file its Form 10-Q and supplementary earnings materials alongside this report,...
Continue Reading
Challenges and Resilience in Reynolds Consumer Products Reynolds Consumer Products Inc. (NASDAQ: REYN) has recently faced a significant decline, hitting a 52-week low of $26.49. This drop reflects the turbulent market conditions affecting the company. Despite this, Reynolds displays a strong financial health posture, with a current ratio of 2.03, showcasing its liquidity...
Continue Reading
Stephen Lackey Family of Companies Sponsorship Announcement The Stephen Lackey Family of Companies (SLFC) is thrilled to announce its role as the Presenting Sponsor for the inaugural 2025 Las Vegas HBCU Classic. This exciting event, featuring a highly anticipated matchup between Jackson State University and Grambling State University, is scheduled to take place on...
Continue Reading
Insights into Volaris' Traffic Growth in March 2025 In a dynamic market, traffic results for Volaris show an upward trajectory for March 2025. Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE: VLRS and BMV: VOLAR) has reported a noticeable increase in operational metrics, a sign of the company's effective strategies in the highly competitive airline...
Continue Reading